Abstract:Background: The identification of effective tumor markers is of paramount importance for the early diagnosis, treatment, and prognosis of esophageal squamous cell carcinoma (ESCC). The present study endeavors to identify efficacious serological markers that can differentiate patients with early-stage ESCC from those with benign esophageal lesions and healthy controls (HC). Cystatin-SN (CST1), an active cysteine protease inhibitor belonging to the Cystatin (CST) superfamily, is implicated in the pathogenesis of inflammation and tumorigenesis. The objective of this investigation is to assess the diagnostic, therapeutic, and prognostic potential of serum CST1 in ESCC. Methods: In our prior RNA sequencing and screening endeavors, we have identified ten genes that are up-regulated in relation to esophageal cancer. Subsequently, we have verified the gene CST1 from the transcriptome data of the The Cancer Genome Atlas Program (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) database. Following this, we conducted an enzyme-linked immunosorbent assay (ELISA) to ascertain the expression levels of CST1 in serum samples from clinical cohorts. Results: The study revealed a significant elevation in serum CST1 levels among patients with early-stage esophageal squamous cell carcinoma (ESCC) (7.41 ± 4.32 ng/ml) compared to those with esophageal benign lesions (4.67 ± 2.43 ng/ml) (p < 0.0001) and healthy controls (4.87 ± 2.77 ng/ml) (p < 0.0001). The diagnostic sensitivity of CST1 for ESCC was 75.68% (specificity 70.83%, AUC 0.775). Combination of CST1 and SCC-Ag exhibited the AUC up to 0.819. Additionally, serum CST1 levels exhibited a significant decrease at 1-2 weeks post-surgery (4.49 ± 3.31 ng/ml) compared to pre-surgery levels (7.68 ± 3.71 ng/ml) (p<0.0001). Survival analysis demonstrated a strong association between high (844/415-1543 d) or low (1490/645-1710 d) serum CST1 levels at diagnosis and overall survival time (p < 0.001). Furthermore, multivariate regression analysis confirmed CST1 (p=0.024, HR=2.023, 95%CI 1.099–3.725) as an independent prognostic factor. Conclusion: Serum CST1 has the potential to function as a diagnostic indicator for distinguishing early-stage esophageal squamous cell carcinoma (ESCC) from individuals with benign esophageal lesions and healthy individuals. Additionally, it could serve as a prognostic predictor and therapeutic efficacy indicator for patients with ESCC.

Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

Cathepsin F and Fibulin-1 as novel diagnostic biomarkers for brain metastasis of non-small cell lung cancer

Cysteine cathepsin C: a novel potential biomarker for the diagnosis and prognosis of glioma

Identification of Cathepsin B As a Novel Target of Hypoxia-Inducible Factor-1-alpha in HepG2 Cells.

Validation of serum cystatin SN detection for diagnosis and poor prognosis of esophageal squamous cell carcinoma

P-127 * SHOTGUN AND TARGETED PROTEOMICS REVEAL THAT PRE-SURGERY SERUM LEVELS OF LRG1, SAA, AND C4BP MAY REFINE PROGNOSIS OF RESECTED SQUAMOUS CELL LUNG CANCER

Bioinformatics Analyses Indicate That Cathepsin G (CTSG) is a Potential Immune-Related Biomarker in Oral Squamous Cell Carcinoma (OSCC)

Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer.

Identification of Candidate Biomarkers for Early Detection of Human Lung Squamous Cell Cancer by Quantitative Proteomics

Increased expression of cathepsin L: a novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients.

Cathepsin L Interacts with CDK2-AP1 As a Potential Predictor of Prognosis in Patients with Breast Cancer

Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma

Reduced expression of cathepsin F predicts poor prognosis in patients with clear cell renal cell carcinoma

The Potential Role of Cathepsin K in Non-Small Cell Lung Cancer

Cathepsin B: The dawn of tumor therapy

Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers

Cathepsin B may be a potential biomarker in cervical cancer.

Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma